Diabetes management company DreaMed Diabetes disclosed on Monday the receipt of US Food and Drug Administration (FDA) clearance and a CE Mark for its artificial intelligence (AI)-based insulin dosing decision support software DreaMed Advisor Pro.

According to the company, the DreaMed Advisor Pro, an artificial intelligence (AI)-based insulin dosing decision support software, is used by people with Type 1 diabetes (T1D) using insulin pump therapy with continuous glucose sensors and/or blood glucose meters (BGMs).

DreaMed Advisor Pro leverages the power of artificial intelligence to optimize insulin administration in a streamlined and cost-effective manner. DreaMed Advisor Pro has already been incorporated as a decision support system for optimizing insulin pump therapy in several US clinics as part of the quality improvement collaboration of the T1D exchange registry.

The company stated that DreaMed Advisor Pro is a cloud-based digital solution generating insulin delivery recommendations by analyzing information from CGM, self-monitoring blood glucose (SMBG) and insulin pump data. Advisor Pro then sends recommendations to the healthcare provider on how to optimize a patient's insulin pump settings for basal rate, carbohydrate ratio (CR) and correction factor (CF).

In addition, the company has completed a multicentre, multinational, randomised controlled study to evaluate DreaMed Advisor Pro in 112 subjects. The results are being analyzed and will be submitted to peer reviewed journals in the next few months.